Annexon, Inc.
ANNX Nasdaq Pharmaceutical Preparations Financials FY2019โFY2025
Last close ยท Oct 23, 2026
$3.75
1.6%What Annexon, Inc. does
No business description yet.
- Legal name
- Annexon, Inc.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K ยท Mar 30, 2026
- Accession ยท CIK
- 0001193125-26-131782
0001528115
Revenue and margins
Annexon, Inc. had โ of revenue in fiscal 2025.
Net income and earnings per share
Loss periods are shown in red.
Returns on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Cash flow
Free cash flow was โ$186M in fiscal 2025, โ of revenue. Cash from operations minus capital spending.
Dividends, buybacks and share count
Annexon, Inc. returned โ to shareholders in fiscal 2025. The diluted share count rose 12.9%.
Balance sheet
Cash, debt and the ratios that show how comfortably Annexon, Inc. can carry it.
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $243M | $243M | $260M | $312M | $238M |
| Current ratio | 11.4x | 11.1x | 14.7x | 10.4x | 5.7x |
| Quick ratio | 11.4x | 11.1x | 14.7x | 10.4x | 5.7x |
| Total assets | $287M | $285M | $298M | $350M | $278M |
| Total liabilities | $55.1M | $53.9M | $47.1M | $57.0M | $65.9M |
| Shareholders' equity | $232M | $231M | $251M | $293M | $212M |
| Net debt (โ = net cash) | โ | โ | โ | โ | โ |
Insider trades
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. โPlanโ marks trades under a pre-arranged Rule 10b5-1 plan.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
โ
$0.0M
No open-market insider trades in the last 12 months.
Piotroski F-score
Nine pass/fail tests of profitability, funding and efficiency. 8โ9 is strong, 0โ2 weak.
| Test | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|
| Net income is positive | โ | โ | โ | โ | โ | โ | โ |
| Cash from operations is positive | โ | โ | โ | โ | โ | โ | โ |
| Return on assets rose | โ | โ | โ | โ | โ | โ | โ |
| Cash from operations exceeds net income | โ | โ | โ | โ | โ | โ | โ |
| Debt fell relative to assets | โ | โ | โ | โ | โ | โ | โ |
| Current ratio rose | โ | โ | โ | โ | โ | โ | โ |
| Share count didn't rise | โ | โ | โ | โ | โ | โ | โ |
| Gross margin rose | โ | โ | โ | โ | โ | โ | โ |
| Revenue rose relative to assets | โ | โ | โ | โ | โ | โ | โ |
| F-score | โ / 3 | โ / 6 | โ / 6 | โ / 6 | โ / 6 | โ / 6 | โ / 6 |
| Accruals ratio | โ17.7% | โ5.1% | โ7.5% | โ9.0% | โ4.5% | โ6.2% | โ6.5% |
| Altman Z'' | โ22.32 | 34.59 | 3.16 | 1.25 | 1.49 | 1.19 | โ7.93 |
7 years of figures
Amounts in USD. Hover a ratioโs name for its definition.
| Fiscal year | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Research and development | $24.5M | $49.3M | $100M | $113M | $114M | $119M | $185M |
| Operating income | โ$32.5M | โ$63.5M | โ$131M | โ$146M | โ$144M | โ$154M | โ$216M |
| Pretax income | โ$37.2M | โ$63.4M | $130M | $142M | $134M | โ$138M | โ$207M |
| Income tax | $0.0M | โ | โ | $0.0M | $0.0M | $0.0M | $0.0M |
| Net income | โ$37.2M | โ$63.4M | โ$130M | โ$142M | โ$134M | โ$138M | โ$207M |
| Net income to common | โ$38.3M | โ$70.3M | โ$130M | โ$142M | โ | โ$138M | โ$209M |
| Diluted EPS | โ$88.30 | โ$4.15 | โ$3.40 | โ$2.60 | โ$1.77 | โ$1.01 | โ$1.34 |
| Diluted shares | 0.00B | 0.02B | 0.04B | 0.05B | 0.08B | 0.14B | 0.16B |
| Cash flow | |||||||
| Cash from operations | โ$28.4M | โ$53.1M | โ$106M | โ$116M | โ$121M | โ$118M | โ$186M |
| Capital expenditure | $0.3M | $0.5M | $1.7M | $6.5M | $0.2M | $0.0M | $0.1M |
| Free cash flow | โ$28.6M | โ$53.6M | โ$108M | โ$123M | โ$121M | โ$118M | โ$186M |
| Depreciation and amortization | $0.5M | $0.7M | $2.1M | $2.1M | $2.1M | $2.2M | $2.2M |
| Stock-based compensation | $2.0M | $4.9M | $16.3M | $18.5M | $18.2M | $19.4M | $16.4M |
| Balance sheet | |||||||
| Cash and short-term investments | $43.9M | $351M | $243M | $243M | $260M | $312M | $238M |
| Current assets | $45.4M | $354M | $248M | $248M | $264M | $316M | $242M |
| Current liabilities | $4.9M | $10.6M | $21.7M | $22.4M | $17.9M | $30.5M | $42.6M |
| Property and equipment, net | $2.1M | $1.9M | $17.8M | $16.8M | $14.8M | $12.6M | $10.6M |
| Total assets | $49.9M | $356M | $287M | $285M | $298M | $350M | $278M |
| Total liabilities | $6.4M | $11.7M | $55.1M | $53.9M | $47.1M | $57.0M | $65.9M |
| Shareholders' equity | โ$100M | $344M | $232M | $231M | $251M | $293M | $212M |
| Returns | |||||||
| Return on capital employed | โ72.3% | โ18.4% | โ49.3% | โ55.4% | โ51.4% | โ48.2% | โ92.1% |
| Return on equity | โ | โ52.0% | โ45.2% | โ61.3% | โ55.7% | โ50.8% | โ81.9% |
| Return on assets | โ74.5% | โ31.2% | โ40.5% | โ49.6% | โ46.1% | โ42.7% | โ65.9% |
| Return on tangible equity | โ | โ20.4% | โ56.2% | โ61.4% | โ53.6% | โ47.2% | โ98.5% |
| Growth | |||||||
| Share count change | โ | 3,812.9% | 125.9% | 42.7% | 38.4% | 81.6% | 12.9% |
| Financial health | |||||||
| Current ratio | 9.2x | 33.3x | 11.4x | 11.1x | 14.7x | 10.4x | 5.7x |
| Quick ratio | 9.2x | 33.3x | 11.4x | 11.1x | 14.7x | 10.4x | 5.7x |
| Quality scores | |||||||
| Altman Z'' | โ22.3 | 34.6 | 3.2 | 1.3 | 1.5 | 1.2 | โ7.9 |
| Accruals ratio | โ17.7% | โ5.1% | โ7.5% | โ9.0% | โ4.5% | โ6.2% | โ6.5% |
Source: SEC EDGAR XBRL filings (CIK 0001528115). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only โ not investment advice. Check the original filings before relying on any figure.
